C5补充抑制与FcRn调制在一般化骨髓灰质炎严重
Niklas Huntemann1, Lea Gerischer2,3, Meret Herdick2,3
1Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Journal of neurology, neurosurgery, and psychiatry
|January 11, 2025
概括
补充因子C5抑制 (C5IT) 和新生儿Fc受体 (FcRn) 抗剂在治疗严重肌痛症 (MG) 中表现出类似的现实世界的有效性和安全性. 这项研究为这些先进的MG疗法提供了关键的比较数据.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨髓灰质炎 (MG) 是一种自身免疫性神经肌肉结合障碍,导致波动的肌肉衰弱.
- 标准免疫抑制对于MG患者的重要亚组来说是不够的.
- 补充因子C5抑制 (C5IT) 和新生儿Fc受体 (FcRn) 反对是新兴的疗法,实际数据比较有限.
研究的目的:
- 为了比较C5IT和FcRn抗剂在真实世界中的有效性和安全性,在肌痛严重症 (MG) 患者中.
- 为指导耐火MG治疗决策提供关键的比较数据.
- 在治疗开始后的前六个月内评估临床结果和安全性.
主要方法:
- 从8个德国中心的153名MG患者的回顾性分析.
- 患者接受了C5IT (eculizumab,ravulizumab) 或efgartigimod (FcRn对抗剂).
- 倾向性得分匹配 (PSM) 用于比较结果和安全概况.
主要成果:
- 两种C5IT和FcRn抗剂都显示出快速的临床改善和降低了普雷迪尼索隆剂量.
- 根据MG特异性得分,不充分反应率有所不同 (20%-49.1%).
- 在PSM之后,在两组中都观察到MG-日常生活活动 (MG-ADL) 评分的可比降低,其次要结局结果相似.
结论:
- 现实世界的数据表明C5IT和FcRn对抗在严重肌痛性肌痛症 (MG) 之间的有效性和安全性相似.
- 这些发现与一些元分析和对临床试验数据的间接比较形成鲜明对比.
- 该研究为管理耐火性MG患者的临床决策提供了有价值的证据.
更多相关视频
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
11.8K
04:30Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
Published on: March 8, 2024
589
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
01:15Myasthenia Gravis: Diagnostic Tests
614
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
614
01:26Chemical Synapses
8.6K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.6K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
613
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
613
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.5K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.5K
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
388
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
388